Incstar obtains US approval for complement activation enzyme (CAE) assay:
This article was originally published in Clinica
Executive Summary
Incstar (US) has been granted 510(k) clearance by the US FDA for its first-generation complement activation enzyme assay. The product was launched outside the US in the second quarter of this year. The CAE assay provides general information about the patient's immune system in certain diseases including systemic lupus erythematosus, rheumatic disorders and massive tissue injury.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.